RxDoctor Payments Data

Abdollati Ghiathi, DO

Family Medicine · Cuthbert, GANPI 1205839891

Payments from drug & device makers

$416in general payments, 2019–2025

Across 22 payments — averaging $18.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$116
  • Boehringer Ingelheim$64
  • Johnson & Johnson$62
  • AstraZeneca$55
  • Lilly USA, LLC$30
  • Novartis$29
  • plus $61 from 3 others

What the payments were for

  • Food & beverage$416100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$416 in reported general payments places this provider in the 40th percentile of 3,111 family medicine providers in Georgia.

See all family medicine providers in Georgia

Medicare billing

Part B allowed, 2024
$59,061
Medicare patients
285
Services billed
1,073

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide183$218,068
EliquisApixaban312$153,794
JardianceEmpagliflozin122$110,760
FarxigaDapagliflozin Propanediol96$83,315
GenvoyaElviteg/Cob/Emtri/Tenof Alafen20$79,222
XareltoRivaroxaban52$47,732
LinzessLinaclotide45$43,070
JanuviaSitagliptin Phosphate54$37,814
XifaxanRifaximin12$36,514
Tresiba Flextouch U-100Insulin Degludec30$34,697
Tresiba Flextouch U-200Insulin Degludec18$34,407
OzempicSemaglutide34$34,169
TrulicityDulaglutide29$34,140
RybelsusSemaglutide13$30,053
Trelegy ElliptaFluticasone/Umeclidin/Vilanter32$22,226

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$30$252,208212 claims
Boehringer IngelheimJardiance, Tradjenta$64$129,832139 claims
AstraZenecaFarxiga, Breztri Aerosphere$55$91,698109 claims
Novo NordiskOzempic, Rybelsus, Tresiba$116$74,60965 claims
Johnson & JohnsonXarelto$62$47,73252 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan$18$36,51412 claims
Otsuka America Pharmaceutical, Inc.Rexulti$20$17,28412 claims
NovartisEntresto$29$13,72212 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 3,111 family medicine providers in Georgia.

Other family medicine in Cuthbert

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →